P
phagos
AI-powered bacteriophage therapies targeting antimicrobial resistance in animals
About phagos
Phagos is a Paris biotechnology company founded in 2021 by Alexandros Pantalis and Adèle James that develops AI-enhanced bacteriophage therapies for bacterial disease, with an initial focus on animal health where antibiotic resistance constrains livestock productivity. Its patented AI analyses phage and bacterial genomes to predict interactions and design adaptable, personalised phage treatments; the company has obtained authorisation to market personalised phage-based veterinary medicines. In October 2025 Phagos raised a €25 million Series A co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, with Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital and Station F participating, to scale veterinary deployment, advance the AI platform and expand the team toward broader markets including a longer-term path to human health. Sources: Tech.eu 8 Oct 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Suresnes, France
- Employees
- 75
- Open positions
- None listed
- Dealroom signal
- 90.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Sustainable Development Goals, Climate Tech, biotech medtech and e-health, Observatoire Deeptech, Woman Founder, Seal of Excellence EC, observatoire industrial tech, antibiotic, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2025 | $28M | $110M | Acurio Ventures · Hoxton Ventures · Station F · Founders Capital | ↗ |
| GRANTOther financing | Aug 2023 | $1.5M | — | Bpifrance | — |
Growth signals
Latest recorded traffic for phagos is 2.5K monthly website visits, down 32.4% over the last three months. phagos's team grew 47.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Hoxton Ventures
Demea Sustainable Investment
AgFunder
Entrepreneurs First
Grant Aarons- MJMax Jamily
Bpifrance
Series A6 investors entered at this stage
CapAgro
CapHorn
Acurio Ventures
Station F
Founders Capital
Citizen Capital
Other known investors7 additional known investors
HEC Paris Incubator
HEC Paris
Agoranov
GROW
HECTAR Accelerator
Space-F
StartLife
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about phagos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See phagos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.